Could Sugar Tagging in The Brain Help Drive Alzheimer's Disease?

Edited and approved by Stephen C. Rose, PhD, MS

Alzheimer's disease is usually discussed in terms of sticky amyloid plaques, tangled tau proteins, and the slow loss of memory. Those pieces still matter. But a new study adds another layer to the story: the way brain cells decorate proteins with sugar-based molecules. In a 2026 Nature Metabolism paper, researchers reported that brains affected by Alzheimer's disease showed unusually high levels of a process called glycosylation, and that pushing this process up or down changed memory-related behavior in mouse models [1].

Glycosylation sounds technical, but the basic idea is simple. Cells often attach small chains of sugars, called glycans, to proteins and fats. These sugar tags help proteins fold correctly, move to the right place, communicate with other cells, and survive long enough to do their jobs. In the brain, where timing and communication are everything, that kind of molecular labeling can matter a lot. The problem is not glycosylation itself. It is essential biology. The concern raised by the new paper is hyperglycosylation, meaning too much of certain glycan tagging in vulnerable brain tissue.

The finding is important because Alzheimer's is not only a disease of protein buildup. It is also a disease of disturbed cell metabolism. The National Institute on Aging describes Alzheimer's as a progressive brain disorder involving complex changes that begin years before symptoms, with age, genetics, cardiovascular health, inflammation, and other factors all contributing to risk [2]. Other recent work has shown that restoring glucose metabolism in the hippocampus, a memory-related brain region, can improve cognition in several mouse models of Alzheimer's pathology [3]. In plain English, the brain's fuel handling and maintenance systems may help shape how the disease unfolds.

The new study asked whether glycan metabolism belongs in that same conversation. The researchers used spatial molecular imaging, a technique that can map chemicals in thin slices of tissue while preserving where those chemicals sit in the brain. That location matters. A molecule rising in a memory circuit may mean something different from the same molecule rising in an unrelated region. Earlier work from the same research area had already shown that glycan patterns can be imaged in mouse and human Alzheimer's brains [4]. The 2026 study went further by combining human brain samples, two mouse models, isotope tracing, genetic tools, drug experiments, dietary glucosamine experiments, and electronic health record analyses [1].

First, the researchers examined postmortem human brain tissue. They found higher N-glycan signals in Alzheimer's samples than in control samples, including in gray matter regions that contain many neuron cell bodies. They also reported that glycosylation increased across Braak stages, a pathology-based staging system often used to describe how far Alzheimer's-related tau changes have spread. This does not prove by itself that sugar tagging causes Alzheimer's. Postmortem tissue is a snapshot after years of disease. Still, the pattern suggested that hyperglycosylation was not just a random chemical oddity.

To test whether the pattern might be active rather than passive, the team turned to mice. They studied 5xFAD mice, which model amyloid-heavy Alzheimer's biology, and PS19 mice, which model tau-related disease. Both showed increased brain N-glycans in regions tied to memory and neurodegeneration [1]. That matters because amyloid and tau are different starting points. Seeing the same broad glycosylation shift in both models makes it less likely that the finding is just a quirk of one engineered mouse line.

The researchers then asked where the extra sugar tags were coming from. Cells can build new glycans through biosynthesis, or they can recycle pieces from older molecules. Using isotope tracing, a method that follows labeled nutrients as they move through metabolism, the study found evidence that increased glycan biosynthesis was the main driver [1]. This fits with older work showing that brain glycogen can serve as a source of glucosamine used for protein glycosylation [5]. In other words, the brain appears to have internal ways to feed this sugar-tagging system.

The most striking part of the study was the intervention work. When the researchers reduced glycosylation in Alzheimer's mouse models by lowering activity of a pathway enzyme called PGM3, memory-related behavior improved. A separate approach using NGI-1, a compound that inhibits a protein complex needed for N-linked glycosylation, also lowered N-glycan abundance and improved social recognition memory in 5xFAD mice [1]. These were not human treatments. They involved experimental tools delivered into the brain, not pills someone could take. But they strengthen the case that excessive glycosylation can contribute to cognitive problems in these models.

The flip side was glucosamine. Glucosamine is a popular dietary supplement often taken for osteoarthritis symptoms, and government health information describes mixed evidence for joint benefits depending on the condition and preparation [6]. In the new Alzheimer's study, oral glucosamine increased brain glycosylation and worsened social memory behavior in 5xFAD mice [1]. Notably, the same glucosamine approach did not produce the same memory problem in normal wild-type mice. That distinction is important. The paper does not show that glucosamine harms every brain. It suggests that a brain already under Alzheimer's-like metabolic stress may respond differently.

The researchers also looked at real-world medical records. In patients with Alzheimer's disease and related dementias, documented glucosamine use was associated with about a 25 percent higher mortality risk after adjustment for age, sex, and demographics. In people with mild cognitive impairment, glucosamine use was also associated with a higher rate of transition to Alzheimer's disease or related dementia [1]. This is concerning, but it is still observational evidence. Medical records can reveal associations; they cannot fully prove cause and effect. People who take supplements may differ from nonusers in ways that records do not capture.

That caution is especially important because supplements are not regulated like prescription drugs. The U.S. Food and Drug Administration explains that dietary supplement companies are responsible for making sure their products are safe and properly labeled before marketing, while FDA action often occurs after a product is already on the market [7]. For consumers, that means supplement decisions should be made with the same seriousness as medication decisions, especially when someone has a neurological disease, takes multiple drugs, or is medically fragile.

So what should families take from this? Not that glucosamine has been proven to cause Alzheimer's disease. Not that anyone should abruptly stop a supplement without discussing it with a clinician. The fair takeaway is narrower but still practical: if a person has Alzheimer's disease, another dementia diagnosis, or worsening cognitive symptoms, glucosamine deserves a medication-list conversation with a physician or pharmacist. Many people forget to mention supplements because they do not think of them as drugs. In the body, however, they can still affect biology.

The larger scientific message is that Alzheimer's research is widening. Amyloid and tau remain central, but they may not be the whole engine. The new study suggests that altered sugar tagging of proteins could be one metabolic system that pushes vulnerable brain circuits toward dysfunction. The evidence is strongest in the paper's mouse experiments and human tissue analyses, preliminary in its electronic health record findings, and not yet ready to guide a clinical treatment. A well-designed, double-blind clinical trial would be needed to test whether glucosamine truly worsens outcomes in people with Alzheimer's disease and whether safely reducing pathological glycosylation could help.

For now, hyperglycosylation gives scientists a fresh way to think about an old disease. The brain is not just accumulating debris; it is also changing how it fuels, labels, sorts, and maintains its proteins. If future studies confirm this pathway, the next generation of Alzheimer's therapies may include not only plaque- or tau-targeting drugs, but also treatments aimed at restoring healthier metabolic balance inside brain cells.

References

1. Hawkinson TR et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026;8:1410-1425.
2. National Institute on Aging. Alzheimer's Disease Fact Sheet.
3. Minhas PS et al. Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies. Science. 2024;385:eabm6131.
4. Hawkinson TR et al. In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains. Alzheimer's & Dementia. 2022;18:1721-1735.
5. Sun RC et al. Brain glycogen serves as a critical glucosamine cache required for protein glycosylation. Cell Metabolism. 2021;33:1404-1417.e9.
6. National Center for Complementary and Integrative Health. Glucosamine and Chondroitin for Osteoarthritis.
7. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements.